Home > Insider Trading > Filing (0000950170-24-138146)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1744659	Akero Therapeutics Inc.	AKRO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1779308	Catriona Yale	601 Gateway Boulevard Suite 350 South San Francisco CA 94080	Chief Development Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-12-16	24,300	$0.00	95,648	No	4	A	Direct
Common Stock	Acquisiton	2024-12-16	9,074	$21.10	104,722	No	4	M	Direct
Common Stock	Disposition	2024-12-16	9,074	$29.11	95,648	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2024-12-16	9,074	$0.00	9,074	$21.10
Common Stock	Stock Option (Right to Buy)	Acquisiton	2024-12-16	73,700	$0.00	73,700	$29.23

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
20,000		2031-12-07	No	4	M	Direct
73,700		2034-12-15	No	4	A	Direct

Footnotes

These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in eight (8) equal semi-annual installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2024, previously adopted by the Reporting Person.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.72 to $29.49, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
The options are vested and currently exercisable.
This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.